8-K: QuidelOrtho Q2: Cost Savings Boost EBITDA Amid Revenue Dip

QuidelOrtho reported a 330 basis point improvement in adjusted EBITDA margin and achieved $100 million in annualized cost savings in Q2 2025, despite a 3.6% total revenue decrease.

Summary

• Total revenue for Q2 2025 was $614 million, a 3.6% decrease from $637 million in the prior year period, primarily due to lower COVID-19 and Donor Screening revenue.
• Non-respiratory revenue decreased 2% to $567 million, but grew 1% in constant currency excluding Donor Screening.
• Labs revenue increased 4% as reported and 5% in constant currency.
• Immunohematology revenue grew 4% as reported and 3% in constant currency.
• Respiratory revenue declined 20% to $47 million, mainly due to lower COVID-19 revenue.
• GAAP net loss was $255 million, resulting in a GAAP diluted loss per share of $3.77.
• Adjusted diluted earnings per share (EPS) was $0.12, compared to an adjusted diluted loss per share of ($0.07) in the prior year.
• Adjusted EBITDA improved to $107 million from $90 million, with the adjusted EBITDA margin increasing by 330 basis points to 17%.
• The company incurred $179 million in restructuring, integration, and other charges, including $150 million related to the discontinuation of the Savanna platform.

Sentiment

Score: 6

Explanation: The sentiment is cautiously positive. While total revenue declined and GAAP losses widened due to significant one-time charges (Savanna platform discontinuation), the company achieved substantial cost savings, significantly improved adjusted EBITDA and adjusted EPS, and reiterated its full-year guidance. This indicates strong operational execution and a clear strategic direction despite a challenging revenue environment.

Positives

• Adjusted EBITDA margin improved by 330 basis points to 17% in Q2 2025, driven by cost-savings initiatives.
• Achieved $100 million in annualized cost savings from initiatives announced in 2024.
• Labs revenue grew 4% as reported and 5% in constant currency.
• Immunohematology revenue grew 4% as reported and 3% in constant currency.
• Adjusted diluted EPS turned positive at $0.12, up from a loss of ($0.07) in the prior year period.
• Reiterated full-year 2025 financial guidance, indicating confidence in future performance.
• Announced intention to acquire LEX Diagnostics, signaling strategic growth.

Negatives

• Total revenue decreased by 3.6% to $614 million in Q2 2025 compared to the prior year.
• GAAP net loss widened to $255 million from $148 million in the prior year, resulting in a GAAP diluted loss per share of $3.77.
• GAAP operating loss increased to $181 million from $118 million in the prior year.
• Respiratory revenue decreased 20% to $47 million, primarily due to lower COVID-19 revenue.
• Donor Screening revenue significantly decreased by 61.2% to $13.3 million.
• Incurred $179 million in restructuring, integration, and other charges, including a $150 million charge related to the discontinuation of the Savanna platform.

Risks

• Fluctuations in demand for non-respiratory and respiratory products.
• Potential supply chain, production, logistics, distribution, and labor disruptions and challenges.
• Challenges and costs associated with integrating, restructuring, and achieving anticipated synergies from the business combination of Quidel Corporation and Ortho Clinical Diagnostics, or other acquisitions.
• Risk of failure to exercise the option to acquire or complete the proposed acquisition of LEX Diagnostics on the anticipated timeline, or at all, including risks related to LEX Diagnostics' ability to secure FDA clearance and satisfy other customary closing conditions.
• Inability to realize the anticipated benefits of acquisitions, discontinuances of certain business operations (such as the discontinuation of the Savanna platform), or cost-savings and operational improvement initiatives on the anticipated timelines, or at all.
• Delays in the development of, or failures or delays in the receipt of approvals for, new or enhanced products.
• Broader macroeconomic, geopolitical, market, business, competitive, and/or regulatory factors, including those arising from tariffs, trade policies, and global trade relations.

Future Outlook

QuidelOrtho reiterated its full-year 2025 financial guidance, projecting total revenues between $2.60 billion and $2.81 billion, adjusted EBITDA between $575 million and $615 million (22% margin), and adjusted diluted EPS between $2.07 and $2.57. Foreign currency exchange is expected to be neutral for the full year.

Management Comments

• Our second quarter results demonstrate our continuing commitment to commercial and operational execution.
• Our team delivered solid top and bottom-line results while also navigating a challenging global environment.
• We achieved several of our key priorities during the second quarter, including realizing our previously announced $100 million in annualized cost-savings; announcing our intention to acquire LEX Diagnostics; and initiating a major manufacturing site consolidation.
• Based on our year-to-date results, we believe we are well positioned to deliver sustainable value over time for our shareholders, customers, and employees.

Industry Context

The in-vitro diagnostics industry is experiencing shifts, with declining demand for COVID-19 related products impacting overall revenue for companies like QuidelOrtho. However, growth in core diagnostic areas like Labs and Immunohematology, coupled with strategic acquisitions and cost-saving initiatives, indicates a focus on adapting to post-pandemic market dynamics and strengthening foundational business segments. The move towards manufacturing site consolidation reflects a broader industry trend of optimizing operational efficiency.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks. However, the company's focus on achieving significant cost savings and improving adjusted EBITDA margin aligns with broader industry efforts to enhance profitability and operational efficiency in a competitive and evolving diagnostic market.

Stakeholder Impact

• Shareholders: Mixed financial results with a revenue decline but improved adjusted profitability and reaffirmed guidance. The significant non-cash charges related to the Savanna platform discontinuation impact GAAP results but are part of a strategic realignment.
• Employees: Planned headcount reductions are noted as part of manufacturing site consolidation, which will impact some employees.
• Customers: Discontinuation of the Savanna platform may affect customers relying on that product. The acquisition of LEX Diagnostics could expand future product offerings.

Next Steps

• Hold an earnings conference call at 2:00 p.m. Pacific Time / 5:00 p.m. ET on August 5, 2025, to discuss financial results.
• Continue integration and restructuring efforts following the business combination of Quidel Corporation and Ortho Clinical Diagnostics.
• Proceed with the intention to acquire LEX Diagnostics, subject to FDA clearance and other closing conditions.
• Continue major manufacturing site consolidation.

Key Dates

Recommendation

QuidelOrtho is in a transitional phase, marked by strategic restructuring, significant cost-saving achievements, and a planned acquisition. While GAAP financial performance shows a widening loss due to one-time charges, the underlying operational improvements, evidenced by a 330 basis point increase in adjusted EBITDA margin and positive adjusted EPS, are encouraging. The reiteration of full-year guidance suggests management confidence in achieving its targets despite current headwinds. Investors should hold to observe the successful execution of these strategic initiatives, particularly the integration of LEX Diagnostics and the full realization of cost synergies, which are critical for long-term value creation.

Keywords

In-vitro diagnostics, QDEL, QuidelOrtho, Financial Results, Earnings, Medical Devices, Diagnostics, Clinical Labs, Point-of-Care, Transfusion Medicine, EBITDA, Revenue, Cost Savings, Acquisition, LEX Diagnostics, Savanna Platform